Disc Medicine insider trades: Kevin Bitterman disposes 32,174 IRON shares at ~$61
Rhea-AI Filing Summary
Disc Medicine director Kevin Bitterman reported sales of company common stock under a Rule 10b5-1 plan. The Form 4 shows sales on 08/13/2025 of 24,962 shares at a weighted-average price of $61.15 and on 08/14/2025 of 7,212 shares at a weighted-average price of $60.99, conducted pursuant to a 10b5-1 trading plan dated January 31, 2025. The filing lists substantial indirect holdings attributed to investment vehicles: 600,120 shares following the 08/13 sale and 592,908 shares following the 08/14 sale, plus additional holdings of 420,549 shares and 51,000 shares held by named funds. The report was signed by an attorney-in-fact on 08/15/2025.
Positive
- Sales executed under a documented Rule 10b5-1 trading plan, indicating pre-arranged transactions and adherence to insider trading procedures
- Detailed disclosure of indirect ownership structure through named Atlas Venture funds and partners, improving transparency
Negative
- Reporting person sold 32,174 shares across two days at weighted-average prices around $61, which reduces their direct/indirect stake reported on the form
Insights
TL;DR Insider sales were executed under a 10b5-1 plan; reported holdings remain substantial.
The reported dispositions total 32,174 shares sold across two dates at weighted-average prices of $61.15 and $60.99. These sales were made pursuant to a documented 10b5-1 plan, which indicates pre-arranged trading and reduces the likelihood that the transactions reflect opportunistic reactions to nonpublic company developments. The Form 4 also discloses large indirect positions held through multiple Atlas Venture funds, with reported post-sale beneficial ownership figures in the hundreds of thousands of shares.
TL;DR Transactions were pre-planned under a 10b5-1 program and properly disclosed on Form 4.
From a governance and compliance perspective, the filing identifies the use of a 10b5-1 trading plan dated January 31, 2025, and includes the required explanatory footnotes describing indirect holdings through related investment entities. The filing appears to follow disclosure conventions by reporting weighted-average prices and providing the chain of entity ownership for indirect holdings. No amendments or additional tones of noncompliance are recorded in the form provided.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,212 | $60.99 | $440K |
| Sale | Common Stock | 24,962 | $61.15 | $1.53M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Shares were sold pursuant to a Rule 10b5-1 trading plan dated January 31, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.95 to $61.615 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4). These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.95 to $61.11 inclusive. These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any.
